Immunovant, Inc. (IMVT)
Fuera de horario:
Immunovant, Inc.
320 West 37th Street
6th Floor
New York, NY 10018
United States
(917) 580-3099
https://immunovant.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 164
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board | 92.5k | N/D | 1979 |
| Dr. Peter Salzmann M.B.A., M.D. | CEO & Director | 1.02M | N/D | 1968 |
| Ms. Eva Renee Barnett M.B.A. | Chief Financial Officer | 871.07k | N/D | 1981 |
| Dr. William L. Macias M.D., Ph.D. | Chief Medical Officer | 719.88k | N/D | 1959 |
| Dr. Jay S. Stout Ph.D. | Chief Technology Officer | N/D | N/D | 1964 |
| Dr. Chau Cheng M.B.A., Ph.D. | Vice President of Investor Relations | N/D | N/D | N/D |
| Mr. Mark S. Levine | Chief Legal Officer & Corporate Secretary | N/D | N/D | 1973 |
| Ms. Lauren Schrier M.B.A. | Vice President of Marketing | N/D | N/D | N/D |
| Ms. Christine Blodgett | Vice President of Human Resources | N/D | N/D | N/D |
| Dr. Julia G. Butchko Ph.D. | Chief Development Officer | 531k | N/D | 1971 |
Descripción
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Gestión corporativa
La calificación ISS Governance QuickScore de Immunovant, Inc. a partir del 1 de mayo de 2024 es 10. Las puntuaciones principales son Auditoría: 7; Junta: 10; Derechos del accionista: 10; Compensación: 8.
